Waivers for Conflicts of Interest for the March 01, 2010 Meeting of the Cardiovascular and Renal Drugs Advisory Committee
The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.
Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007. This provision was repealed, effective October 1, 2007, by the FDA.
Cardiovascular and Renal Drugs Advisory Committee Meeting March 01, 2010
Richard Mann, M.D.
- Richard Mann, M.D. 18 U.S.C. 208 waivers (PDF - 39KB)
- Richard Mann, M.D. Disclosure Document (PDF - 23KB)